Stalicla Is A Swiss Clinical Stage Biopharmaceutical Company Founded In 2017Dedicated To Developing Precision Medicine Therapies For Neurodevelopmental Disordersndds With A Focus On Autism Spectrum Disorderasd The Company Has Raised Approximately $44 8 Million To Dateincluding A Recent $17 4 Million Series B Funding Roundstalicla Is Headquartered In Switzerland And Aims To Identify Biologically Defined Patient Subgroups To Tailor Treatments For Their Specific Needs The Company Utilizes Its Proprietary Depi Platformwhich Combines Multi Omics Data And Machine Learning To Identify Patient Subgroups With Shared Biological Signaturesthis Platform Has Achieved Clinical Proof Of Conceptwith Its Lead Candidatestp1Currently In Clinical Trials Targeting A Specific Asd Subgroupstalicla Plans To Expand Its Pipeline With Two Phase 2 Clinical Programs By 2024Focusing On Collaborations To Enhance Its Platform And Address Unmet Needs In Severely Affected Patient Populations
